Topical Estriol for Vaginal Health

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00908570
Recruitment Status : Completed
First Posted : May 27, 2009
Last Update Posted : March 4, 2011
University of Illinois at Chicago
University of California, Los Angeles
Tulane University School of Medicine
Magee-Women's Research Institute
Oregon Health and Science University
Information provided by:
Gynuity Health Projects

Brief Summary:
The purpose of this Phase I study is to investigate and document the effects of local treatment with a topical estriol cream on the vaginal environment of pre-menopausal women.

Condition or disease Intervention/treatment Phase
Vaginal Health Drug: estriol Drug: Placebo Phase 1

Detailed Description:

There is evidence from human studies that estrogen can give rise to health-promoting changes in the vaginal environment in addition to affecting the thickness of the vaginal epithelium. The purpose of the proposed study is to take the first steps in testing the effects of local estrogen treatment on vaginal health parameters in humans. We have chosen an estriol product because, in comparison with estrone (E1) and estradiol (E2), estriol (E3) is generally considered to be a weak estrogen. The duration of estriol's interaction with the estrogen receptor is quick and exhibits rapid metabolic clearance. We have chosen a topical route of administration because it appears to result in fewer systemic effects than oral administration, while allowing us to concentrate treatment locally in the areas we wish to affect.

Our primary goal is to test whether or not topically applied estrogen results in significant thickening and maturation of the vaginal epithelium. Our secondary goal is to measure the treatment's effects on other parameters of the vagina, such as Lactobacillus colonization and vaginal pH. If estrogen cream does indeed affect the vaginal environment in pre-menopausal women as it does in post-menopausal women, further study would be indicated to determine whether estrogen cream in the vagina decreases risk of infection in pre-menopausal women.

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 104 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Care Provider)
Primary Purpose: Prevention
Official Title: Topical Estriol for Vaginal Health
Study Start Date : June 2009
Actual Primary Completion Date : March 2011
Actual Study Completion Date : March 2011

Resource links provided by the National Library of Medicine

Drug Information available for: Estriol
U.S. FDA Resources

Arm Intervention/treatment
Experimental: 1Topical estriol cream Drug: estriol
4 ml vaginal cream (1.0 mg estriol/1 ml cream), 3 days/week for approximately 2 months.
Placebo Comparator: 2Placebo cream Drug: Placebo
Placebo cream

Primary Outcome Measures :
  1. Change in thickness of the vaginal epithelium [ Time Frame: Pre and post treatment luteal and follicular phases ]

Secondary Outcome Measures :
  1. Other vaginal parameters including Lactobacillus colonization and vaginal pH [ Time Frame: Pre and post treatment follicular and luteal phases ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 40 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • In generally good health
  • Between the ages of 18 and 40
  • Report regular, consistent menstrual cycles with duration between 25 and 35 days' duration
  • Agree not to initiate hormonal contraception or other systemic or vaginal hormonal treatments during the course of the study
  • Agree to refrain from vaginal douching and use of spermicides, spermicide-treated condoms, diaphragms, cervical caps, vaginal hygiene treatments and other vaginal products during the course of the study except as explicitly allowed under study protocol.
  • Not attempting to get pregnant (and, if sexually active, using an allowed effective contraceptive - i.e., sterilization or male condoms)

Exclusion Criteria:

  • Has been informed by a health practitioner that she should avoid estrogen treatments
  • Does not meet one or more of the above inclusion criteria
  • Is currently pregnant
  • Is currently lactating
  • Has IUD in place
  • Has diabetes that is controlled with medication
  • Has menstrual bleeding that usually exceeds 7 days' duration
  • Has used hormonal contraception or other systemic or vaginal hormonal treatment during the past three months
  • Has received systemic antibiotic treatment since the start of bleeding in her current menstrual period
  • Has known history of diagnosis of HIV infection
  • Screens positive for gonorrhea, Chlamydia, or trichomonas
  • Has evidence of high-grade dysplasia or cervical cancer on visual examination or Pap smear
  • Has active genital Herpes lesions
  • Has any of the following:
  • Known, past or suspected breast cancer;
  • Known or suspected estrogen-dependent malignant or pre-malignant tumours (e.g endometrial cancer);
  • History of endometrial hyperplasia;
  • Undiagnosed or abnormal genital bleeding;
  • Previous idiopathic or current venous thromboembolism (deep venous thrombosis, pulmonary embolism);
  • Active or recent arterial thromboembolic disease (e.g. angina, myocardial infarction);
  • Acute liver disease, or a history of liver disease where liver function tests have failed to return to normal;
  • Liver disorders such as adenomas;
  • Symptomatic gallstones or gallbladder disease (cholecystitis);
  • Hypertriglyceridemia;
  • Vascular disease associated with lupus erythematosus;
  • Known hypersensitivity to estriol (estrogen E3) or the inactive substances in the study product;
  • Porphyria
  • Presents any other history or condition that provider, in his or her best discretion, feels should rule out study participation.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00908570

United States, California
Harbor-UCLA Medical Center
Los Angeles, California, United States, 90502
United States, Illinois
University of Illinois at Chicago
Chicago, Illinois, United States, 60612
Sponsors and Collaborators
Gynuity Health Projects
University of Illinois at Chicago
University of California, Los Angeles
Tulane University School of Medicine
Magee-Women's Research Institute
Oregon Health and Science University
Principal Investigator: Yael Swica, M.D., M.P.H. Gynuity Health Projects

Responsible Party: Beverly Winikoff, MD, MPH, Gynuity Health Projects Identifier: NCT00908570     History of Changes
Other Study ID Numbers: 5.1
First Posted: May 27, 2009    Key Record Dates
Last Update Posted: March 4, 2011
Last Verified: March 2011

Keywords provided by Gynuity Health Projects:
infection prevention